BL_genes.md
... ...
@@ -0,0 +1,553 @@
1
+# BL genes
2
+
3
+## Origins of BL genes![sankey](BL_sankey-1.svg)
4
+
5
+## Tier 1 BL genes
6
+
7
+| Gene | Tier | Relevant references |
8
+|:------------------:|:----:|:-------------------------------------------------------------:|
9
+| [ARID1A](ARID1A) | 1 | Love et al. 2012; Krysiak et al. 2017; Zhang et al. 2013 |
10
+| [BMP7](BMP7) | 1 | Panea et al. 2019 |
11
+| [CCND3](CCND3) | 1 | Morin et al. 2011; Richter et al. 2012 |
12
+| [CHD8](CHD8) | 1 | Grande et al. 2019; Reddy et al. 2017 |
13
+| [DDX3X](DDX3X) | 1 | Schmitz et al. 2012, 2018 |
14
+| [EIF4A1](EIF4A1) | 1 | Panea et al. 2019 |
15
+| [EPPK1](EPPK1) | 1 | Panea et al. 2019 |
16
+| [FBXO11](FBXO11) | 1 | Hübschmann et al. 2021; Richter et al. 2012 |
17
+| [FOXO1](FOXO1) | 1 | Schmitz et al. 2012; Morin et al. 2011 |
18
+| [GNA13](GNA13) | 1 | Love et al. 2012; Morin et al. 2011 |
19
+| [GNAI2](GNAI2) | 1 | Grande et al. 2019; Morin et al. 2013 |
20
+| [HNRNPU](HNRNPU) | 1a | Reddy et al. 2017; Panea et al. 2019 |
21
+| [ID3](ID3) | 1 | Schmitz et al. 2012; Richter et al. 2012 |
22
+| [KMT2D](KMT2D) | 1 | Morin et al. 2011; Grande et al. 2019 |
23
+| [MYC](MYC) | 1a | Johnston and Carroll 1992; L. Pasqualucci et al. 2001 |
24
+| [P2RY8](P2RY8) | 1 | Muppidi et al. 2014; Lohr et al. 2012 |
25
+| [PHF6](PHF6) | 1 | Reddy et al. 2017; Thomas et al. 2023 |
26
+| [PTEN](PTEN) | 1 | Love et al. 2012 |
27
+| [RFX7](RFX7) | 1 | Grande et al. 2019 |
28
+| [RHOA](RHOA) | 1 | Richter et al. 2012 |
29
+| [SIN3A](SIN3A) | 1 | Grande et al. 2019 |
30
+| [SMARCA4](SMARCA4) | 1 | Krysiak et al. 2017; Richter et al. 2012; Zhang et al. 2013 |
31
+| [TCF3](TCF3) | 1 | Schmitz et al. 2012 |
32
+| [TCL1A](TCL1A) | 1 | Grande et al. 2019 |
33
+| [TFAP4](TFAP4) | 1 | Grande et al. 2019 |
34
+| [TP53](TP53) | 1 | Morin et al. 2011; Wilda et al. 2004 |
35
+| [USP7](USP7) | 1 | Grande et al. 2019 |
36
+| [WNK1](WNK1) | 1 | Hübschmann et al. 2021; Thomas et al. 2023 |
37
+
38
+## Tier 2 BL genes
39
+
40
+| Gene | Tier | Relevant references |
41
+|:----------------------:|:----:|:-------------------------------------------------------------------:|
42
+| [ACAD9](ACAD9) | 2 | Love et al. 2012 |
43
+| [ACE](ACE) | 2 | Love et al. 2012 |
44
+| [ADAMTS5](ADAMTS5) | 2 | Burkhardt et al. 2022 |
45
+| [ADNP](ADNP) | 2 | Burkhardt et al. 2022 |
46
+| [AGO4](AGO4) | 2 | Burkhardt et al. 2022 |
47
+| [ALPK2](ALPK2) | 2 | Panea et al. 2019 |
48
+| [ARHGEF1](ARHGEF1) | 2 | Muppidi et al. 2014 |
49
+| [ATP2C2](ATP2C2) | 2 | Love et al. 2012 |
50
+| [BACH2](BACH2) | 2a | Grande et al. 2019 |
51
+| [BCL2](BCL2) | 2a | Burkhardt et al. 2022; Morin et al. 2011; Tanaka et al. 1992 |
52
+| [BCL6](BCL6) | 2a | Love et al. 2012; Morin et al. 2011 |
53
+| [BCL7A](BCL7A) | 2a | Grande et al. 2019; Krysiak et al. 2017; Arthur et al. 2018 |
54
+| [BRAF](BRAF) | 2 | Love et al. 2012; Tiacci et al. 2011 |
55
+| [BRD4](BRD4) | 2 | Love et al. 2012 |
56
+| [BTG1](BTG1) | 2a | Morin et al. 2011; Burkhardt et al. 2022 |
57
+| [BTG2](BTG2) | 2a | Love et al. 2012; Morin et al. 2011 |
58
+| [C16orf48](C16orf48) | 2 | Schmitz et al. 2012 |
59
+| [C6orf27](C6orf27) | 2 | Love et al. 2012 |
60
+| [CAD](CAD) | 2 | Love et al. 2012 |
61
+| [CARD11](CARD11) | 2 | Lenz et al. 2008; Morin et al. 2011; Panea et al. 2019 |
62
+| [CARD4](CARD4) | 2 | Love et al. 2012 |
63
+| [CCNF](CCNF) | 2 | Abate et al. 2015 |
64
+| [CCT6B](CCT6B) | 2 | Love et al. 2012 |
65
+| [CD79A](CD79A) | 2 | Burkhardt et al. 2022 |
66
+| [CD79B](CD79B) | 2 | Morin et al. 2011; Panea et al. 2019 |
67
+| [CD83](CD83) | 2a | Morin et al. 2013; Panea et al. 2019; Russler-Germain et al. 2023 |
68
+| [CDC73](CDC73) | 2 | Reddy et al. 2017; Love et al. 2012 |
69
+| [CDH17](CDH17) | 2 | Love et al. 2012 |
70
+| [CDKN2A](CDKN2A) | 2 | Morin et al. 2013; Grande et al. 2019 |
71
+| [CDKN2C](CDKN2C) | 2 | Thomas et al. 2023 |
72
+| [CHD4](CHD4) | 2 | Burkhardt et al. 2022 |
73
+| [COL4A2](COL4A2) | 2 | Love et al. 2012 |
74
+| [CPXM2](CPXM2) | 2 | Burkhardt et al. 2022 |
75
+| [CREBBP](CREBBP) | 2 | Love et al. 2012; Laura Pasqualucci, Dominguez-Sola, et al. 2011 |
76
+| [CTCF](CTCF) | 2 | Panea et al. 2019 |
77
+| [CXCR4](CXCR4) | 2a | Krysiak et al. 2017; Khodabakhshi et al. 2012; Panea et al. 2019 |
78
+| [CYB5D1](CYB5D1) | 2 | Love et al. 2012 |
79
+| [CYP4F22](CYP4F22) | 2 | Love et al. 2012 |
80
+| [DHCR7](DHCR7) | 2 | Schmitz et al. 2012 |
81
+| [DLGAP1](DLGAP1) | 2 | Love et al. 2012 |
82
+| [DNMT1](DNMT1) | 2 | Panea et al. 2019 |
83
+| [DTX1](DTX1) | 2a | Panea et al. 2019; Schmitz et al. 2018 |
84
+| [E2F2](E2F2) | 2 | Burkhardt et al. 2022 |
85
+| [EBF1](EBF1) | 2a | Bohle et al. 2013; Thomas et al. 2023 |
86
+| [EDNRB](EDNRB) | 2 | Burkhardt et al. 2022 |
87
+| [EHD1](EHD1) | 2 | Thomas et al. 2023 |
88
+| [EIF2C4](EIF2C4) | 2 | Love et al. 2012 |
89
+| [ELP2](ELP2) | 2 | Schmitz et al. 2012 |
90
+| [EML2](EML2) | 2 | Love et al. 2012 |
91
+| [ENTPD3](ENTPD3) | 2 | Love et al. 2012 |
92
+| [EP300](EP300) | 2 | Laura Pasqualucci, Dominguez-Sola, et al. 2011; Panea et al. 2019 |
93
+| [EPHB2](EPHB2) | 2 | Love et al. 2012 |
94
+| [ERAP1](ERAP1) | 2 | Burkhardt et al. 2022 |
95
+| [ETS1](ETS1) | 2a | Panea et al. 2019; Morin et al. 2011 |
96
+| [EXOSC6](EXOSC6) | 2 | Schmitz et al. 2012 |
97
+| [EZH2](EZH2) | 2 | Morin et al. 2010; Love et al. 2012 |
98
+| [FAM129B](FAM129B) | 2 | Love et al. 2012 |
99
+| [FGFR3](FGFR3) | 2 | Love et al. 2012 |
100
+| [FLYWCH1](FLYWCH1) | 2 | Schmitz et al. 2012 |
101
+| [FTCD](FTCD) | 2 | Love et al. 2012 |
102
+| [FZD3](FZD3) | 2 | Panea et al. 2019 |
103
+| [GGTLA4](GGTLA4) | 2 | Love et al. 2012 |
104
+| [GRB2](GRB2) | 2 | Laura Pasqualucci, Trifonov, et al. 2011; Panea et al. 2019 |
105
+| [GRIK5](GRIK5) | 2 | Love et al. 2012 |
106
+| [GTSE1](GTSE1) | 2 | Schmitz et al. 2012 |
107
+| [HIST1H1C](HIST1H1C) | 2a | Panea et al. 2019; Morin et al. 2011 |
108
+| [HIST1H1E](HIST1H1E) | 2a | Morin et al. 2013; Grande et al. 2019; Krysiak et al. 2017 |
109
+| [HIST1H2AG](HIST1H2AG) | 2a | Morin et al. 2013; Krysiak et al. 2017; Panea et al. 2019 |
110
+| [HIST1H2AM](HIST1H2AM) | 2a | Panea et al. 2019; Krysiak et al. 2017 |
111
+| [HIST1H2BK](HIST1H2BK) | 2a | Panea et al. 2019 |
112
+| [HIST1H3D](HIST1H3D) | 2a | Panea et al. 2019 |
113
+| [HIST1H3H](HIST1H3H) | 2a | Panea et al. 2019 |
114
+| [HIST1H3I](HIST1H3I) | 2a | Panea et al. 2019; Krysiak et al. 2017 |
115
+| [HIST1H3J](HIST1H3J) | 2a | Panea et al. 2019 |
116
+| [HIST1H4J](HIST1H4J) | 2a | Panea et al. 2019 |
117
+| [HLA-A](HLA-A) | 2 | |
118
+| [HLA-B](HLA-B) | 2 | |
119
+| [HLA-DMB](HLA-DMB) | 2 | |
120
+| [HLA-DQB1](HLA-DQB1) | 2 | Burkhardt et al. 2022 |
121
+| [ICK](ICK) | 2 | Love et al. 2012 |
122
+| [IGLL5](IGLL5) | 2a | Russler-Germain et al. 2023; Panea et al. 2019 |
123
+| [IKZF3](IKZF3) | 2a | Panea et al. 2019; Morin et al. 2013 |
124
+| [IRF8](IRF8) | 2a | Panea et al. 2019; Morin et al. 2011 |
125
+| [ITPR3](ITPR3) | 2 | Love et al. 2012 |
126
+| [KANK2](KANK2) | 2 | Schmitz et al. 2012 |
127
+| [KCNK10](KCNK10) | 2 | Panea et al. 2019 |
128
+| [KIFC3](KIFC3) | 2 | Love et al. 2012 |
129
+| [KLHL26](KLHL26) | 2 | Burkhardt et al. 2022 |
130
+| [KLHL6](KLHL6) | 2a | Morin et al. 2011; Panea et al. 2019 |
131
+| [KMT2C](KMT2C) | 2 | Zhou et al. 2019; Zhang et al. 2013 |
132
+| [LTB](LTB) | 2a | Panea et al. 2019; Chapuy et al. 2018 |
133
+| [MAP3K6](MAP3K6) | 2 | Love et al. 2012 |
134
+| [MCL1](MCL1) | 2 | Panea et al. 2019; Reddy et al. 2017 |
135
+| [MIR142](MIR142) | 2a | Grande et al. 2019; Kwanhian et al. 2012 |
136
+| [MKI67](MKI67) | 2 | Russler-Germain et al. 2023; Schmitz et al. 2012 |
137
+| [MME](MME) | 2 | Panea et al. 2019 |
138
+| [MTOR](MTOR) | 2 | Zhang et al. 2013; Panea et al. 2019 |
139
+| [MYH10](MYH10) | 2 | Love et al. 2012 |
140
+| [MYO18A](MYO18A) | 2 | Schmitz et al. 2012 |
141
+| [NBEAL1](NBEAL1) | 2 | Love et al. 2012 |
142
+| [NCOR2](NCOR2) | 2 | Schmitz et al. 2012 |
143
+| [NOA1](NOA1) | 2 | Burkhardt et al. 2022 |
144
+| [NOTCH1](NOTCH1) | 2 | Laura Pasqualucci, Trifonov, et al. 2011; Love et al. 2012 |
145
+| [NOTCH2](NOTCH2) | 2 | Trøen et al. 2008; Panea et al. 2019 |
146
+| [NRXN2](NRXN2) | 2 | Love et al. 2012 |
147
+| [P2RY2](P2RY2) | 2 | Love et al. 2012 |
148
+| [PABPC4L](PABPC4L) | 2 | Panea et al. 2019 |
149
+| [PC](PC) | 2 | Love et al. 2012 |
150
+| [PCBP1](PCBP1) | 2 | Schmitz et al. 2012 |
151
+| [PCDHA11](PCDHA11) | 2 | Panea et al. 2019 |
152
+| [PDCD11](PDCD11) | 2 | Schmitz et al. 2012 |
153
+| [PDZRN3](PDZRN3) | 2 | Panea et al. 2019 |
154
+| [PIK3R1](PIK3R1) | 2 | Zhang et al. 2013; Panea et al. 2019 |
155
+| [PIM1](PIM1) | 2a | L. Pasqualucci et al. 2001; Burkhardt et al. 2022 |
156
+| [PLCG2](PLCG2) | 2 | Panea et al. 2019 |
157
+| [POLRMT](POLRMT) | 2 | Love et al. 2012 |
158
+| [POR](POR) | 2 | Love et al. 2012 |
159
+| [PPP6R2](PPP6R2) | 2 | Burkhardt et al. 2022 |
160
+| [PREX1](PREX1) | 2 | Burkhardt et al. 2022 |
161
+| [PRSS22](PRSS22) | 2 | Love et al. 2012 |
162
+| [PTPRN](PTPRN) | 2 | Love et al. 2012 |
163
+| [PXDNL](PXDNL) | 2 | Panea et al. 2019 |
164
+| [RAC2](RAC2) | 2 | Hübschmann et al. 2021; Panea et al. 2019 |
165
+| [RANBP6](RANBP6) | 2 | Love et al. 2012 |
166
+| [RBP3](RBP3) | 2 | Love et al. 2012 |
167
+| [RET](RET) | 2 | Love et al. 2012 |
168
+| [REV3L](REV3L) | 2 | Burkhardt et al. 2022 |
169
+| [RNF144B](RNF144B) | 2 | Panea et al. 2019 |
170
+| [RPL10](RPL10) | 2 | Burkhardt et al. 2022 |
171
+| [S1PR2](S1PR2) | 2a | Morin et al. 2011; Muppidi et al. 2014 |
172
+| [SAL3](SAL3) | 2 | Burkhardt et al. 2022 |
173
+| [SALL3](SALL3) | 2 | Love et al. 2012 |
174
+| [SAPS2](SAPS2) | 2 | Love et al. 2012 |
175
+| [SBF1](SBF1) | 2 | Love et al. 2012 |
176
+| [SF3B1](SF3B1) | 2 | Love et al. 2012 |
177
+| [SHANK1](SHANK1) | 2 | Love et al. 2012 |
178
+| [SLC29A2](SLC29A2) | 2 | Love et al. 2012 |
179
+| [SNTB2](SNTB2) | 2 | Panea et al. 2019 |
180
+| [SP3](SP3) | 2 | Panea et al. 2019 |
181
+| [SYNCRIP](SYNCRIP) | 2 | Panea et al. 2019 |
182
+| [SYNGAP1](SYNGAP1) | 2 | Love et al. 2012 |
183
+| [TBC1D9B](TBC1D9B) | 2 | Love et al. 2012 |
184
+| [TET2](TET2) | 2 | Albuquerque et al. 2017; Panea et al. 2019 |
185
+| [TIGD6](TIGD6) | 2 | Love et al. 2012 |
186
+| [TOP2A](TOP2A) | 2 | Schmitz et al. 2012 |
187
+| [TPST2](TPST2) | 2 | Love et al. 2012 |
188
+| [TTN](TTN) | 2 | Burkhardt et al. 2022 |
189
+| [VWA7](VWA7) | 2 | Burkhardt et al. 2022 |
190
+| [WDR7](WDR7) | 2 | Panea et al. 2019 |
191
+| [WDR90](WDR90) | 2 | Schmitz et al. 2012 |
192
+| [WHAMM](WHAMM) | 2 | Schmitz et al. 2012 |
193
+| [WNK2](WNK2) | 2 | Panea et al. 2019 |
194
+| [YY1AP1](YY1AP1) | 2 | Schmitz et al. 2012 |
195
+| [ZAN](ZAN) | 2 | Burkhardt et al. 2022 |
196
+| [ZBTB7A](ZBTB7A) | 2 | Burkhardt et al. 2022; Reddy et al. 2017 |
197
+| [ZFP36L1](ZFP36L1) | 2a | Morin et al. 2011; Panea et al. 2019 |
198
+| [ZNF229](ZNF229) | 2 | Love et al. 2012 |
199
+| [ZNF85](ZNF85) | 2 | Burkhardt et al. 2022 |
200
+
201
+# References
202
+
203
+<div id="refs" class="references csl-bib-body hanging-indent">
204
+
205
+<div id="ref-abateDistinctViralMutational2015a" class="csl-entry">
206
+
207
+Abate, F., M. Ambrosio, L. Mundo, M. Laginestra, F. Fuligni, M. Rossi,
208
+Sakellarios Zairis, et al. 2015. “Distinct Viral and Mutational Spectrum
209
+of Endemic Burkitt Lymphoma.” *PLoS Pathogens* 11.
210
+<https://doi.org/10.1371/journal.ppat.1005158>.
211
+
212
+</div>
213
+
214
+<div id="ref-albuquerqueEnhancingKnowledgeDiscovery2017a"
215
+class="csl-entry">
216
+
217
+Albuquerque, Marco A., Bruno M. Grande, Elie J. Ritch, Prasath
218
+Pararajalingam, Selin Jessa, Martin Krzywinski, Jasleen K. Grewal,
219
+Sohrab P. Shah, Paul C. Boutros, and Ryan D. Morin. 2017. “Enhancing
220
+Knowledge Discovery from Cancer Genomics Data with Galaxy.”
221
+*GigaScience* 6 5: 1–13. <https://doi.org/10.1093/gigascience/gix015>.
222
+
223
+</div>
224
+
225
+<div id="ref-arthurGenomewideDiscoverySomatic2018" class="csl-entry">
226
+
227
+Arthur, Sarah E., Aixiang Jiang, Bruno M. Grande, Miguel Alcaide, Razvan
228
+Cojocaru, Christopher K. Rushton, Anja Mottok, et al. 2018. “Genome-Wide
229
+Discovery of Somatic Regulatory Variants in Diffuse Large <span
230
+class="nocase">B-cell</span> Lymphoma.” *Nature Communications* 9 1:
231
+4001. <https://doi.org/10.1038/s41467-018-06354-3>.
232
+
233
+</div>
234
+
235
+<div id="ref-bohleRoleEarlyBcell2013" class="csl-entry">
236
+
237
+Bohle, V., C. Döring, M.-L. Hansmann, and R. Küppers. 2013. “Role of
238
+Early <span class="nocase">B-cell</span> Factor 1 EBF1 in Hodgkin
239
+Lymphoma.” *Leukemia* 27 3: 671–79.
240
+<https://doi.org/10.1038/leu.2012.280>.
241
+
242
+</div>
243
+
244
+<div id="ref-burkhardtClinicalRelevanceMolecular2022b"
245
+class="csl-entry">
246
+
247
+Burkhardt, Birgit, Ulf Michgehl, Jonas Rohde, Tabea Erdmann, Philipp
248
+Berning, Katrin Reutter, Marius Rohde, et al. 2022. “Clinical Relevance
249
+of Molecular Characteristics in Burkitt Lymphoma Differs According to
250
+Age.” *Nature Communications* 13 1: 3881.
251
+<https://doi.org/10.1038/s41467-022-31355-8>.
252
+
253
+</div>
254
+
255
+<div id="ref-chapuyMolecularSubtypesDiffuse2018b" class="csl-entry">
256
+
257
+Chapuy, Bjoern, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Atanas
258
+Kamburov, Robert A. Redd, Mike S. Lawrence, et al. 2018. “Molecular
259
+Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct
260
+Pathogenic Mechanisms and Outcomes.” *Nature Medicine* 24 5: 679–90.
261
+<https://doi.org/10.1038/s41591-018-0016-8>.
262
+
263
+</div>
264
+
265
+<div id="ref-grandeGenomewideDiscoverySomatic2019" class="csl-entry">
266
+
267
+Grande, Bruno M., Daniela S. Gerhard, Aixiang Jiang, Nicholas B. Griner,
268
+Jeremy S. Abramson, Thomas B. Alexander, Hilary Allen, et al. 2019.
269
+“Genome-Wide Discovery of Somatic Coding and Noncoding Mutations in
270
+Pediatric Endemic and Sporadic Burkitt Lymphoma.” *Blood* 133 12:
271
+1313–24. <https://doi.org/10.1182/blood-2018-09-871418>.
272
+
273
+</div>
274
+
275
+<div id="ref-hubschmannMutationalMechanismsShaping2021b"
276
+class="csl-entry">
277
+
278
+Hübschmann, Daniel, Kortine Kleinheinz, Rabea Wagener, Stephan H.
279
+Bernhart, Cristina López, Umut H. Toprak, Stephanie Sungalee, et al.
280
+2021. “Mutational Mechanisms Shaping the Coding and Noncoding Genome of
281
+Germinal Center Derived <span class="nocase">B-cell</span> Lymphomas.”
282
+*Leukemia* 35 7: 2002–16.
283
+<https://doi.org/10.1038/s41375-021-01251-z>.
284
+
285
+</div>
286
+
287
+<div id="ref-johnstonCmycHypermutationBurkitt1992" class="csl-entry">
288
+
289
+Johnston, J. M., and W. L. Carroll. 1992. “C-Myc Hypermutation in
290
+Burkitt’s Lymphoma.” *Leukemia & Lymphoma* 8 6: 431–39.
291
+<https://doi.org/10.3109/10428199209051025>.
292
+
293
+</div>
294
+
295
+<div id="ref-khodabakhshiRecurrentTargetsAberrant2012"
296
+class="csl-entry">
297
+
298
+Khodabakhshi, Alireza Hadj, Ryan D. Morin, Anthony P. Fejes, Andrew J.
299
+Mungall, Karen L. Mungall, Madison Bolger-Munro, Nathalie A. Johnson, et
300
+al. 2012. “Recurrent Targets of Aberrant Somatic Hypermutation in
301
+Lymphoma.” *Oncotarget* 3 11: 1308–19.
302
+<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717795/>.
303
+
304
+</div>
305
+
306
+<div id="ref-krysiakRecurrentSomaticMutations2017b" class="csl-entry">
307
+
308
+Krysiak, Kilannin, Felicia Gomez, Brian S. White, Matthew Matlock,
309
+Christopher A. Miller, Lee Trani, Catrina C. Fronick, et al. 2017.
310
+“Recurrent Somatic Mutations Affecting <span
311
+class="nocase">B-cell</span> Receptor Signaling Pathway Genes in
312
+Follicular Lymphoma.” *Blood* 129 4: 473–83.
313
+<https://doi.org/10.1182/blood-2016-07-729954>.
314
+
315
+</div>
316
+
317
+<div id="ref-kwanhianMicroRNA142Mutated202012b" class="csl-entry">
318
+
319
+Kwanhian, Wiyada, Dido Lenze, Julia Alles, Natalie Motsch, Stephanie
320
+Barth, Celina Döll, Jochen Imig, et al. 2012. “MicroRNA-142 Is Mutated
321
+in about 20% of Diffuse Large <span class="nocase">B-cell</span>
322
+Lymphoma.” *Cancer Medicine* 1 2: 141–55.
323
+<https://doi.org/10.1002/cam4.29>.
324
+
325
+</div>
326
+
327
+<div id="ref-lenzOncogenicCARD11Mutations2008" class="csl-entry">
328
+
329
+Lenz, Georg, R Eric Davis, Vu N Ngo, Lloyd Lam, Thaddeus C George,
330
+George W Wright, Sandeep S Dave, et al. 2008. “Oncogenic CARD11
331
+Mutations in Human Diffuse Large B Cell Lymphoma.” *Science* 319 5870:
332
+1676–79.
333
+
334
+</div>
335
+
336
+<div id="ref-lohrDiscoveryPrioritizationSomatic2012a" class="csl-entry">
337
+
338
+Lohr, Jens G., Petar Stojanov, Michael S. Lawrence, Daniel Auclair,
339
+Bjoern Chapuy, Carrie Sougnez, Peter Cruz-Gordillo, et al. 2012.
340
+“Discovery and Prioritization of Somatic Mutations in Diffuse Large
341
+<span class="nocase">B-cell</span> Lymphoma DLBCL by Whole-Exome
342
+Sequencing.” *Proceedings of the National Academy of Sciences of the
343
+United States of America* 109 10: 3879–84.
344
+<https://doi.org/10.1073/pnas.1121343109>.
345
+
346
+</div>
347
+
348
+<div id="ref-loveGeneticLandscapeMutations2012" class="csl-entry">
349
+
350
+Love, Cassandra, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney
351
+Miles, Kristy L. Richards, et al. 2012. “The Genetic Landscape of
352
+Mutations in Burkitt Lymphoma.” *Nature Genetics* 44 12: 1321–25.
353
+<https://doi.org/10.1038/ng.2468>.
354
+
355
+</div>
356
+
357
+<div id="ref-morinSomaticMutationsAltering2010a" class="csl-entry">
358
+
359
+Morin, Ryan D., Nathalie A. Johnson, Tesa M. Severson, Andrew J.
360
+Mungall, Jianghong An, Rodrigo Goya, Jessica E. Paul, et al. 2010.
361
+“Somatic Mutations Altering EZH2 Tyr641 in Follicular and Diffuse
362
+Large <span class="nocase">B-cell</span> Lymphomas of Germinal-Center
363
+Origin.” *Nature Genetics* 42 2: 181–85.
364
+<https://doi.org/10.1038/ng.518>.
365
+
366
+</div>
367
+
368
+<div id="ref-morinFrequentMutationHistonemodifying2011"
369
+class="csl-entry">
370
+
371
+Morin, Ryan D., Maria Mendez-Lago, Andrew J. Mungall, Rodrigo Goya,
372
+Karen L. Mungall, Richard D. Corbett, Nathalie A. Johnson, et al. 2011.
373
+“Frequent Mutation of Histone-Modifying Genes in Non-Hodgkin Lymphoma.”
374
+*Nature* 476 7360: 298–303. <https://doi.org/10.1038/nature10351>.
375
+
376
+</div>
377
+
378
+<div id="ref-morinMutationalStructuralAnalysis2013" class="csl-entry">
379
+
380
+Morin, Ryan D., Karen Mungall, Erin Pleasance, Andrew J. Mungall,
381
+Rodrigo Goya, Ryan D. Huff, David W. Scott, et al. 2013. “Mutational and
382
+Structural Analysis of Diffuse Large <span class="nocase">B-cell</span>
383
+Lymphoma Using Whole-Genome Sequencing.” *Blood* 122 7: 1256–65.
384
+<https://doi.org/10.1182/blood-2013-02-483727>.
385
+
386
+</div>
387
+
388
+<div id="ref-muppidiLossSignalingGa132014b" class="csl-entry">
389
+
390
+Muppidi, J., R. Schmitz, Jesse A. Green, Jesse A. Green, Wenming Xiao,
391
+Adrien B. Larsen, S. Braun, et al. 2014. “Loss of Signaling via Gα13 in
392
+Germinal Center B Cell-Derived Lymphoma.” *Nature* 516: 254–58.
393
+<https://doi.org/10.1038/nature13765>.
394
+
395
+</div>
396
+
397
+<div id="ref-paneaWholeGenomeLandscape2019" class="csl-entry">
398
+
399
+Panea, R., C. Love, Jennifer R. Shingleton, Anupama Reddy, J. Bailey, A.
400
+Moormann, J. Otieno, et al. 2019. “The Whole Genome Landscape of Burkitt
401
+Lymphoma Subtypes.” *Blood*. <https://doi.org/10.1182/blood.2019001880>.
402
+
403
+</div>
404
+
405
+<div id="ref-pasqualucciInactivatingMutationsAcetyltransferase2011a"
406
+class="csl-entry">
407
+
408
+Pasqualucci, Laura, David Dominguez-Sola, Annalisa Chiarenza, Giulia
409
+Fabbri, Adina Grunn, Vladimir Trifonov, Lawryn H. Kasper, et al. 2011.
410
+“Inactivating Mutations of Acetyltransferase Genes in <span
411
+class="nocase">B-cell</span> Lymphoma.” *Nature* 471 7337: 189–95.
412
+<https://doi.org/10.1038/nature09730>.
413
+
414
+</div>
415
+
416
+<div id="ref-pasqualucciAnalysisCodingGenome2011" class="csl-entry">
417
+
418
+Pasqualucci, Laura, Vladimir Trifonov, Giulia Fabbri, Jing Ma, Davide
419
+Rossi, Annalisa Chiarenza, Victoria A. Wells, et al. 2011. “Analysis of
420
+the Coding Genome of Diffuse Large <span class="nocase">B-cell</span>
421
+Lymphoma.” *Nature Genetics* 43 9: 830–37.
422
+<https://doi.org/10.1038/ng.892>.
423
+
424
+</div>
425
+
426
+<div id="ref-pasqualucciHypermutationMultipleProtooncogenes2001a"
427
+class="csl-entry">
428
+
429
+Pasqualucci, L., P. Neumeister, T. Goossens, G. Nanjangud, R. S.
430
+Chaganti, R. Küppers, and R. Dalla-Favera. 2001. “Hypermutation of
431
+Multiple Proto-Oncogenes in <span class="nocase">B-cell</span> Diffuse
432
+Large-Cell Lymphomas.” *Nature* 412 6844: 341–46.
433
+<https://doi.org/10.1038/35085588>.
434
+
435
+</div>
436
+
437
+<div id="ref-reddyGeneticFunctionalDrivers2017" class="csl-entry">
438
+
439
+Reddy, Anupama, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt,
440
+Cassandra L Love, Alexander Waldrop, Sirpa Leppa, et al. 2017. “Genetic
441
+and Functional Drivers of Diffuse Large B Cell Lymphoma.” *Cell* 171
442
+2: 481–494.e15.
443
+
444
+</div>
445
+
446
+<div id="ref-richterRecurrentMutationID32012a" class="csl-entry">
447
+
448
+Richter, Julia, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen
449
+Leich, Birgit Burkhardt, Maciej Rosolowski, et al. 2012. “Recurrent
450
+Mutation of the ID3 Gene in Burkitt Lymphoma Identified by Integrated
451
+Genome, Exome and Transcriptome Sequencing.” *Nature Genetics* 44 12:
452
+1316–20. <https://doi.org/10.1038/ng.2469>.
453
+
454
+</div>
455
+
456
+<div id="ref-russler-germainMutationsAssociatedProgression2023b"
457
+class="csl-entry">
458
+
459
+Russler-Germain, David A., Kilannin Krysiak, Cody A. Ramirez, Matthew
460
+Mosior, Marcus P. Watkins, Felicia Gomez, Zachary L. Skidmore, et al.
461
+2023. “Mutations Associated with Progression in Follicular Lymphoma
462
+Predict Inferior Outcomes at Diagnosis: Alliance A151303.” *Blood
463
+Advances* 7: 5524–39.
464
+<https://doi.org/10.1182/bloodadvances.2023010779>.
465
+
466
+</div>
467
+
468
+<div id="ref-schmitzGeneticsPathogenesisDiffuse2018a" class="csl-entry">
469
+
470
+Schmitz, Roland, George W. Wright, Da Wei Huang, Calvin A. Johnson,
471
+James D. Phelan, James Q. Wang, Sandrine Roulland, et al. 2018.
472
+“Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.” *The New
473
+England Journal of Medicine* 378 15: 1396–1407.
474
+<https://doi.org/10.1056/NEJMoa1801445>.
475
+
476
+</div>
477
+
478
+<div id="ref-schmitzBurkittLymphomaPathogenesis2012" class="csl-entry">
479
+
480
+Schmitz, Roland, Ryan M. Young, Michele Ceribelli, Sameer Jhavar,
481
+Wenming Xiao, Meili Zhang, George Wright, et al. 2012. “Burkitt Lymphoma
482
+Pathogenesis and Therapeutic Targets from Structural and Functional
483
+Genomics.” *Nature* 490 7418: 116–20.
484
+<https://doi.org/10.1038/nature11378>.
485
+
486
+</div>
487
+
488
+<div id="ref-tanakaFrequentIncidenceSomatic1992" class="csl-entry">
489
+
490
+Tanaka, S., D. C. Louie, J. A. Kant, and J. C. Reed. 1992. “Frequent
491
+Incidence of Somatic Mutations in Translocated BCL2 Oncogenes of
492
+Non-Hodgkin’s Lymphomas.” *Blood* 79 1: 229–37.
493
+
494
+</div>
495
+
496
+<div id="ref-thomasGeneticSubgroupsInform2023" class="csl-entry">
497
+
498
+Thomas, Nicole, Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton,
499
+Jeremy S. Abramson, Richard F. Ambinder, Stefan Barta, et al. 2023.
500
+“Genetic Subgroups Inform on Pathobiology in Adult and Pediatric Burkitt
501
+Lymphoma.” *Blood* 141 8: 904–16.
502
+<https://doi.org/10.1182/blood.2022016534>.
503
+
504
+</div>
505
+
506
+<div id="ref-tiacciBRAFMutationsHairycell2011a" class="csl-entry">
507
+
508
+Tiacci, Enrico, Vladimir Trifonov, Gianluca Schiavoni, Antony Holmes,
509
+Wolfgang Kern, Maria Paola Martelli, Alessandra Pucciarini, et al. 2011.
510
+“BRAF Mutations in Hairy-Cell Leukemia.” *The New England Journal of
511
+Medicine* 364 24: 2305–15. <https://doi.org/10.1056/NEJMoa1014209>.
512
+
513
+</div>
514
+
515
+<div id="ref-troenNOTCH2MutationsMarginal2008" class="csl-entry">
516
+
517
+Trøen, Gunhild, Iwona Wlodarska, Abdirashid Warsame, Silvia Hernández
518
+Llodrà, Christiane De Wolf-Peeters, and Jan Delabie. 2008. “NOTCH2
519
+Mutations in Marginal Zone Lymphoma.” *Haematologica* 93 7: 1107–9.
520
+<https://doi.org/10.3324/haematol.11635>.
521
+
522
+</div>
523
+
524
+<div id="ref-wildaInactivationARFMDM2p53Pathway2004" class="csl-entry">
525
+
526
+Wilda, M., J. Bruch, L. Harder, D. Rawer, A. Reiter, A. Borkhardt, and
527
+W. Woessmann. 2004. “Inactivation of the <span
528
+class="nocase">ARF-MDM-2-p53</span> Pathway in Sporadic Burkitt’s
529
+Lymphoma in Children.” *Leukemia* 18 3: 584–88.
530
+<https://doi.org/10.1038/sj.leu.2403254>.
531
+
532
+</div>
533
+
534
+<div id="ref-zhangGeneticHeterogeneityDiffuse2013" class="csl-entry">
535
+
536
+Zhang, Jenny, Vladimir Grubor, Cassandra L Love, Anjishnu Banerjee,
537
+Kristy L Richards, Piotr A Mieczkowski, Cherie Dunphy, et al. 2013.
538
+“Genetic Heterogeneity of Diffuse Large <span
539
+class="nocase">B-cell</span> Lymphoma.” January.
540
+
541
+</div>
542
+
543
+<div id="ref-zhouSporadicEndemicBurkitt2019" class="csl-entry">
544
+
545
+Zhou, Peixun, Alex E. Blain, Alexander M. Newman, Masood Zaka, George
546
+Chagaluka, Filbert R. Adlar, Ugonna T. Offor, et al. 2019. “Sporadic and
547
+Endemic Burkitt Lymphoma Have Frequent FOXO1 Mutations but Distinct
548
+Hotspots in the AKT Recognition Motif.” *Blood Advances* 3 14:
549
+2118–27. <https://doi.org/10.1182/bloodadvances.2018029546>.
550
+
551
+</div>
552
+
553
+</div>